Welcome to Pfizer’s News & Media Center—designed to give you immediate access to timely and relevant information about our company. In this section you will find information and resources for journalists including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.
Important New Mylotarg Information
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg.
- Press release
- Acute Myeloid Leukemia (AML) Fact Sheet
- Prescribing Information
- Dear Healthcare Professional Letter
NEW YORK, July 29 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Established Products, at the BMO Capital Markets 10th Annual Focus On Healthcare Conference on Thursday, August 5, 2010 at 11:15 a.m. Eastern Daylight Time.
Woodcliff Lake, NJ, and New York, July 23, 2010 Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer’s disease (AD).
NEW YORK, July 22 /PRNewswire-FirstCall/ -- As part of its commitment to improving the quality of patient care, Pfizer (NYSE: PFE) today announced that it will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders.
NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab.
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Samsung Medical Center and the world's leading bio-pharmaceutical company Pfizer Inc. (NYSE: PFE) announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.
HONOLULU, July 13 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations.
Recent Press Statements
Clinical Trials
April 21, 2010 — Pfizer Statement on Conducting Clinical Trial
Pfizer's Collaboration with Healthcare Professionals and Clinical Investigators
Additional Press Statements
Trovan / Nigeria Clinical Study
Intellectual Property and American Competitiveness
Teleconference: Prevenar 13
Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.
Investor Presentations
Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.
Executive Speeches & Commentary
View Executive Leadership speeches on a variety of topics.
Pfizer Pipeline Update – Our Medicines in Development
Visit the Pfizer Pipeline to learn more about exciting breakthroughs with our medicines in development. With the largest pipeline in the pharmaceutical industry, Pfizer and our partners are focusing on discovering and developing new medicines across 10 therapeutic areas.
Stay on top of Pfizer breaking news: Get News Alerts by RSS.
Follow us
Pfizer Twitter Community
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Jul 30 2010 4:00PM
| Last 15.00 | Change -0.09 |
| %Change | -0.60 | Vol. | 44,031,495 |
| Day High | 15.13 | 52 Wk. High | 20.36 |
| Day Low | 14.88 | 52 Wk. Low | 14.00 |
| Open | 15.02 | Mkt. Cap(Bil) | 120.99 |
| Prev. Close | 15.09 |
Our press kit provides information that might help you write stories or simply find out more about Pfizer.
Access Pfizer images and videos including product logos, headshots, and video clips.
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2010 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
